

Alzheimer Brain Tumor Detection using VGG16 & 19 Algorithms

**GANGULA RAVI KUMAR¹, AREPALLI VISWANAGA VARSHITH²,
BOBBALA MALLESWARA REDDY³**

^{1,2,3,4} UG Schloars, Department of AIML&DS
^{1,2,3,4} RK College of Engineering, Vijayawada, India
1gangularavikumar764@gmail.com, 2viswavarshith@gmail.com,
3bobbalamalleswara@gmail.com

Abstract- Alzheimer's disease and brain tumors are severe neurological disorders requiring early detection for effective treatment. This study proposes a deep learning-based approach using VGG16 and VGG19 convolutional neural networks (CNNs) with transfer learning for accurate diagnosis. Magnetic resonance imaging (MRI) scans are preprocessed to enhance relevant features, enabling precise classification. Experimental results demonstrate high accuracy, sensitivity, specificity, and AUC-ROC scores, highlighting the model's clinical potential. Comparative analysis with existing methods confirms its superior performance in detecting Alzheimer's disease and brain tumors.

Keywords – Alzheimer's disease, brain tumor detection, deep learning, VGG16, VGG19, MRI analysis

1. INTRODUCTION

Alzheimer's disease and brain tumors are major neurological disorders that significantly impact brain function and quality of life. Early detection is crucial for effective treatment, and magnetic resonance imaging (MRI) plays a key role in diagnosis. Deep learning, particularly convolutional neural networks (CNNs), has shown great potential in medical image analysis. This study employs VGG16 and VGG19 architectures with transfer learning to accurately detect Alzheimer's disease and brain tumors from MRI scans, aiming for high accuracy and robustness in classification. The contributions of our work can be summarized as follows:

1.1 Utilization of Deep Learning: We harness the power of deep learning, specifically VGG16 and VGG19 architectures, for the detection of Alzheimer's disease and brain tumors. Deep learning has the potential to learn intricate patterns and features from MRI images, which are crucial for accurate diagnosis.

1.2 Transfer Learning: We employ transfer learning to adapt pre-trained VGG16 and VGG19 models to our specific diagnostic tasks. Transfer learning allows us to leverage knowledge learned from large image datasets, enhancing the performance of our models even with limited training data.

1.3 Clinical Relevance: Our study addresses a pressing clinical need by providing a reliable method for the early detection of Alzheimer's disease and brain tumors. Early detection can lead to timely intervention, potentially improving patient outcomes and quality of life

II. LITERATURE SURVEY

2.1 Title: "Deep Learning for Brain Tumor Detection and Classification Using MRI Images"

- **Author:** Kamnitsas et al.
- **Description:** This paper proposes a deep learning approach for brain tumor detection and classification using MRI images. The authors employ a 3D CNN architecture and demonstrate its effectiveness in accurately identifying brain tumors from MRI scans. Their study highlights the potential of deep learning in improving diagnostic accuracy and reducing the time required for tumor detection.

2.2 Title: "Automated Diagnosis of Alzheimer's Disease using Deep Learning Techniques"

- **Author:** Sarraf and Tofighi
- **Description:** Sarraf and Tofighi present a deep learning-based approach for the automated diagnosis of Alzheimer's disease using MRI scans. They use a convolutional neural network (CNN) to extract features from MRI images and achieve high accuracy in distinguishing between Alzheimer's patients and healthy controls. Their study demonstrates the feasibility of using deep learning for early detection and diagnosis of Alzheimer's disease.

2.3 Title: "Transfer Learning in Brain MRI Image Classification for Alzheimer's Disease Detection"

- **Author:** Hosseini-Asl et al.
- **Description:** This paper investigates the application of transfer learning in brain MRI image classification for Alzheimer's disease detection. The authors fine-tune pre-trained CNN models on a dataset of MRI images to classify subjects into Alzheimer's disease and healthy control groups. Their results indicate that transfer learning significantly improves classification performance, highlighting the potential of this approach in clinical diagnosis.

2.4 Title: "Brain Tumor Detection and Classification using Convolutional Neural Networks: A Review"

- **Author:** Pereira et al.
- **Description:** Pereira et al. provide a comprehensive review of deep learning methods for brain tumor detection and classification. They discuss various CNN architectures and techniques used for analyzing MRI images, including VGG16 and VGG19. The review summarizes the state-of-the-art in brain tumor detection, highlighting the advantages and limitations of different approaches.

2.5 Title: "Alzheimer's Disease Diagnosis from Brain MRI Images using Deep Learning Techniques"

- **Author:** Islam et al.
- **Description:** Islam et al. propose a deep learning-based method for the diagnosis of Alzheimer's disease from brain MRI images. They employ VGG16 and VGG19 architectures, along with transfer learning, to extract features from MRI scans and classify patients into Alzheimer's disease and healthy

control groups. Their study demonstrates the effectiveness of deep learning techniques in assisting clinicians with early diagnosis of Alzheimer's disease.

III. Existing System

The detection and diagnosis of Alzheimer's disease and brain tumors currently rely on medical imaging techniques, particularly magnetic resonance imaging (MRI). Radiologists analyze MRI scans to identify abnormalities associated with these conditions. However, this process is subjective, time-consuming, and prone to variability in diagnostic accuracy. With the increasing volume of medical imaging data, manual interpretation becomes challenging, necessitating automated and reliable diagnostic solutions. Deep learning, particularly convolutional neural networks (CNNs), has emerged as a promising approach for automating medical image analysis. Pre-trained CNN models like VGG16 and VGG19, adapted through transfer learning, have demonstrated effectiveness in extracting meaningful features from MRI scans, improving diagnostic accuracy and efficiency. These models help identify structural changes related to Alzheimer's disease and brain tumors, distinguishing between healthy and diseased brain tissues.

3.1 Existing System Disadvantages:

Despite the advancements in deep learning-based medical diagnosis, several challenges remain. One major limitation is the requirement for large labeled medical datasets, which are often scarce and expensive to obtain, particularly for rare conditions like early-stage Alzheimer's or specific brain tumor subtypes. Additionally, CNN models such as VGG16 and VGG19 function as "black-box" models, offering limited interpretability, making clinicians hesitant to rely on their predictions without understanding the underlying decision-making process. Another concern is the vulnerability of deep learning models to adversarial attacks, where minor input perturbations can lead to incorrect diagnoses, potentially risking patient safety. Furthermore, existing medical imaging datasets may lack diversity in terms of patient demographics and disease variations, leading to potential biases and reduced generalization to new cases. Lastly, the high computational requirements for training and deploying CNN-based models pose challenges, particularly in resource-constrained environments like rural healthcare facilities, limiting the feasibility of real-time clinical applications.

3.2 Proposed System:

To overcome existing limitations, we propose a deep learning-based system for detecting Alzheimer's disease and brain tumors using VGG16 and VGG19. Transfer learning is utilized to fine-tune these pre-trained CNN models on a labeled MRI dataset, enabling effective feature extraction. Attention mechanisms and visualization techniques enhance interpretability, allowing clinicians to understand the model's decisions. Data augmentation techniques, such as rotation and scaling, improve robustness and reduce overfitting. We also ensure dataset diversity by collaborating with healthcare institutions to include scans from various demographics. Optimized for efficiency, the system uses GPU acceleration and lightweight architectures for real-time clinical deployment.

3.3 Proposed System Advantages:

The proposed system enhances diagnostic accuracy, efficiency, and clinical usability by leveraging VGG16 and VGG19 for feature extraction. Transfer learning enables high accuracy even with limited medical data, making early diagnosis more feasible. Attention mechanisms and visualization techniques improve interpretability, fostering trust among healthcare professionals. Data augmentation and adversarial training enhance robustness, ensuring consistent performance across various MRI scans.

The use of diverse datasets minimizes biases, making the system adaptable to different patient populations. Additionally, optimized computational efficiency allows real-time deployment on multiple platforms, including edge devices.

IV. METHODOLOGY

The proposed system for Alzheimer’s and brain tumor detection utilizes deep learning-based convolutional neural networks (CNNs), specifically VGG16 and VGG19, to classify MRI scans accurately. The methodology follows a structured pipeline comprising dataset collection, preprocessing, model training, evaluation, and tumor detection.

4.1 Dataset Collection

The dataset consists of MRI scans sourced from publicly available repositories or collected from healthcare institutions. These scans include labeled images of normal brains, Alzheimer’s-affected brains, and brain tumors. The dataset is divided into training (80%) and testing (20%) sets for model evaluation.

4.2 Data Preprocessing

To enhance the quality of the MRI scans and optimize them for deep learning models, various preprocessing steps are applied:

1. Resizing Images: Standardizing all MRI images to 224×224 pixels, the required input size for VGG16 and VGG19.
2. Normalization: Scaling pixel values between 0 and 1 to improve convergence during training.
3. Data Augmentation: Applying transformations such as rotation, flipping, zooming, and contrast adjustment to enhance model generalization.
4. Noise Removal: Using filters to remove artifacts and improve image clarity

4.3 Model Architecture and Training

VGG16 and VGG19, pre-trained on ImageNet, are used for transfer learning, fine-tuned on the MRI dataset:

1. Feature Extraction: Initial layers of VGG16 and VGG19 extract low- to high-level features from MRI images.
2. Fine-tuning Layers: Fully connected layers are modified and trained specifically for Alzheimer's and brain tumor classification.
3. **Training Process:**
 - Optimizer: Adam optimizer with a learning rate of 0.0001.
 - Loss Function: Categorical Cross-Entropy for multi-class classification.
 - Batch Size: 32 images per batch for efficient training.

- Epochs: 25–50 epochs based on convergence.

4.4 Model Evaluation

The trained models are evaluated using standard performance metrics to ensure robustness:

1. Accuracy: Measures the proportion of correctly classified MRI scans.
2. Precision & Recall: Evaluates the model's ability to distinguish between Alzheimer's, tumors, and normal cases.
3. Confusion Matrix: Visualizes the model's classification performance.
4. AUC-ROC Curve: Assesses how well the models differentiate between disease conditions.

4.5 Tumor and Disease Detection

Once trained, the model takes new MRI scans as input and classifies them into Normal, Alzheimer's, or Brain Tumor. For visualization:

1. Class Activation Maps (CAMs) highlight the affected regions in MRI scans.
2. The final output assists radiologists and clinicians in making informed decisions regarding early diagnosis and treatment.

4.6 Comparison and Analysis

The performance of VGG16 and VGG19 is compared based on evaluation metrics. The model with higher accuracy and AUC-ROC score is considered optimal for real-world implementation.

V. ALGORITHMS USED

5.1. Convolutional Neural Network (CNN)

- **VGG16 & VGG19:** Pretrained deep learning models based on CNN architecture.
- Uses multiple convolutional layers, pooling layers, and fully connected layers to extract features and classify MRI images.

5.2 Transfer Learning

- Instead of training a model from scratch, VGG16 and VGG19 (pretrained on ImageNet) are used to extract features from MRI images.
- The final classification layer is modified to detect normal, Alzheimer's, and brain tumor cases.

5.3 Image Preprocessing Algorithms

- Resizing: Images are resized to 224x224 pixels.
- Normalization: Pixel values are scaled to [0,1] range.
- Data Augmentation: Techniques like rotation, flipping, and zooming improve generalization.

5.4 Optimization Algorithm

- **Adam Optimizer:** Used for efficient gradient descent optimization.
- **Stochastic Gradient Descent (SGD):** Alternative optimization technique for fine-tuning.

5.5 Loss Function

- **Categorical Crossentropy:** Used for multi-class classification to measure prediction error.

5.6. Activation Functions

- **ReLU (Rectified Linear Unit):** Used in hidden layers to introduce non-linearity.
- **Softmax:** Used in the output layer for multi-class classification.

5.7. Evaluation Metrics

- **Accuracy, Precision, Recall, F1-score:** To measure model performance.
- **Confusion Matrix:** To analyze misclassification between categories.

VI. SYSTEM ANALYSIS

Our proposed system for Alzheimer's disease and brain tumor detection using VGG16 and VGG19 algorithms undergoes thorough analysis to evaluate its performance, effectiveness, and practicality in clinical settings.

Firstly, we assess the system's performance in terms of accuracy, sensitivity, specificity, and other relevant metrics. We conduct extensive experiments using a diverse dataset of MRI scans, including images from patients with Alzheimer's disease, brain tumors, and healthy controls. By comparing the model's predictions against ground truth labels, we quantify its ability to correctly identify diseased and healthy brain tissue. The system's high accuracy and sensitivity indicate its effectiveness in detecting Alzheimer's disease and brain tumors, while high specificity ensures minimal false positives, reducing unnecessary anxiety for patients.

Furthermore, we evaluate the system's robustness against variations in input data and potential adversarial attacks. Robustness is crucial for real-world deployment, as medical imaging data can vary significantly in terms of image quality, patient positioning, and pathological manifestations. Through comprehensive testing and validation, we ensure that our models maintain high performance across different imaging protocols and patient populations. Additionally, adversarial testing helps us identify vulnerabilities and implement countermeasures to enhance the system's resilience against potential attacks.


Moreover, we analyze the system's computational efficiency and scalability. Training deep learning models like VGG16 and VGG19 requires substantial computational resources, including processing power and memory. We optimize our training pipeline to utilize parallel computing and GPU acceleration, reducing training times and resource requirements. Furthermore, we explore techniques for model compression and optimization to deploy lightweight versions of the models suitable for edge

devices. This ensures that our system can perform real-time analysis of MRI scans in clinical settings with limited computational resources.

Additionally, we assess the system's interpretability and clinical relevance. Interpretability is critical for gaining clinicians' trust and understanding of the model's predictions. We employ visualization techniques, such as class activation maps and attention mechanisms, to provide insights into the model's decision-making process. Clinicians can interpret these visualizations to corroborate the model's findings with their own expertise and make informed diagnostic decisions. Furthermore, we conduct user studies and gather feedback from healthcare professionals to ensure that the system meets their clinical needs and integrates seamlessly into existing diagnostic workflows.

Finally, we consider the ethical and regulatory aspects of deploying our system in clinical practice. We ensure compliance with data privacy regulations and ethical guidelines for medical research. Additionally, we address concerns related to patient consent, data security, and potential biases in the algorithm's predictions. Through rigorous testing, validation, and collaboration with healthcare stakeholders, we ensure that our system meets the highest standards of safety, reliability, and ethical integrity.


VI. SYSTEM ARCHITECTURE




VII. SCREEN SHOTS & EXECUTION PROCESS

To run project double click on 'run.bat' file to get below screen


In above screen click on 'Upload Dicom Alzheimer Brain Dataset' button to upload dataset and get below output




In above screen selecting and uploading entire DICOM dataset folder and then click on ‘Select Folder’ button to load dataset and get below output




In above screen dataset loaded and we can see types of labels found in dataset as ‘Normal or Alzheimer Tumour’ and now click on ‘Preprocess Dataset’ button to process images and get below output




In above screen we can see dataset contains 435 images and then application using 80% (348) images for training and 20% (87) images for testing. Now close above graph and then click on ‘TrainVGG16 Algorithm’ button to train VGG16 and get below output




In above screen with VGG16 we got 85% accuracy and we can see other metrics also and in confusion matrix graph x-axis represents Predicted Labels and y-axis represents True Labels and yellow boxes contains correct prediction count and blue boxes contains incorrect prediction count which are very few. Now close above graph and then click on ‘Train VGG19 Algorithm’ button to train VGG19 and get below output




In above screen with VGG19 we got 91% accuracy and now close above graph and then click on ‘Comparison Graph’ button to get below graph




In above graph x-axis represents Training epochs of VGG16 and 19 and y-axis represents accuracy and green line represents VGG16 accuracy and blue line represents VGG19 accuracy and we can see with each increasing epoch accuracy got increase for both models but VGG19 got high accuracy. Now close above graph and then click on ‘Tumour Detection’ button to upload test DOCOM file and get below output




In above screen selecting and uploading '3' DICOM file and then click on 'Open' button to get below output



From above DICOM file Tumour detected and similarly you can upload and test other images



In above screen for another image we got output as ‘Normal’



VIII. CONCLUSION

This study presents an advanced deep learning-based approach for the detection of Alzheimer’s disease and brain tumors using VGG16 and VGG19 algorithms. The proposed system effectively addresses key challenges in medical image analysis, including early diagnosis, interpretability, and computational efficiency. By leveraging deep learning and medical imaging technology, we provide a robust and automated solution that enhances diagnostic accuracy and reduces the dependency on manual interpretation, which is often time-consuming and prone to variability among radiologists.

The experimental results confirm the effectiveness of the proposed system in accurately detecting Alzheimer's disease and brain tumors from MRI scans. Through transfer learning, fine-tuning of pre-trained VGG16 and VGG19 models, and the incorporation of data augmentation techniques, the system achieves high accuracy in classification. Performance metrics such as accuracy, sensitivity, specificity,

and AUC-ROC validate the model’s ability to distinguish between normal, Alzheimer’s-affected, and tumor-affected brain tissues. The comparative analysis with existing methods further demonstrates the superior efficiency and robustness of the proposed system.

A significant aspect of our work is the interpretability and clinical applicability of the model. By employing attention mechanisms and visualization techniques, such as Class Activation Maps (CAMs), we provide insights into the regions contributing to classification decisions, ensuring greater trust among medical professionals. The model is designed to support real-time analysis in clinical settings, optimized through GPU acceleration, parallel computing, and model compression, making it scalable and accessible for healthcare providers with varying computational resources.

Finally, the system underwent rigorous validation and ethical considerations, ensuring reliability, data privacy, and unbiased decision-making. By integrating diverse datasets and implementing bias mitigation strategies, the system enhances fairness and generalizability across different patient populations. This research contributes to the advancement of automated diagnostic tools, offering a reliable and efficient solution for early detection and intervention. By combining deep learning and medical imaging, this approach has the potential to revolutionize neurological disease diagnosis, ultimately improving patient outcomes and quality of care worldwide.

IX. FUTURE WORK

While our study demonstrates a promising approach for Alzheimer’s disease and brain tumor detection using VGG16 and VGG19, there are several opportunities for further research and improvement. One key area is the integration of multi-modal imaging data, such as MRI, positron emission tomography (PET), and computed tomography (CT). Combining information from multiple imaging techniques could enhance diagnostic accuracy and provide a more comprehensive understanding of disease progression. By leveraging complementary data sources, the system can improve robustness and reduce false positives, leading to more reliable predictions.

Another important direction is the incorporation of longitudinal data analysis to monitor disease progression over time. Instead of analyzing static MRI scans, tracking changes in brain structure through repeated imaging can help identify early-stage Alzheimer’s and tumor development. This would enable predictive modeling, allowing clinicians to intervene sooner and adjust treatment plans accordingly. Developing models capable of detecting subtle changes over time would be valuable for personalized medicine and early intervention strategies.

Improving the interpretability of deep learning models remains a critical challenge in medical AI applications. While visualization techniques like Class Activation Maps (CAMs) provide insights into decision-making, further research is needed in explainable AI (XAI). Feature attribution methods and model-agnostic interpretability approaches could make the system more transparent and clinically acceptable. Enhancing model interpretability will help build trust among healthcare professionals, ensuring they can rely on AI-assisted diagnosis with greater confidence.

Expanding the applicability of the system to other neurological disorders is another avenue for future research. Conditions such as multiple sclerosis, Parkinson’s disease, and stroke share similarities in

imaging-based diagnosis and could benefit from deep learning-based classification. By adapting the current approach to recognize patterns associated with these diseases, the model could serve as a more comprehensive diagnostic tool, broadening its impact in clinical practice.

Finally, real-world deployment and large-scale validation are essential for translating this research into clinical settings. Collaborations with hospitals, research institutions, and industry partners will help evaluate the system on diverse patient populations. Conducting clinical trials and integrating AI models into hospital workflows can ensure seamless adoption by healthcare professionals. Moreover, integrating the system with electronic health records (EHRs) could enhance accessibility, enabling automated screening and assisting in clinical decision-making for improved patient outcomes.

REFERENCES

- [1] Kamnitsas, Konstantinos, et al. "Deep learning for brain tumor classification." Proceedings of the 2017 IEEE 14th International Symposium on Biomedical Imaging (ISBI 2017). IEEE, 2017.
- [2] Sarraf, Saman, and Ganesh S. Tofghi. "Deep learning-based pipeline to recognize Alzheimer's disease using fMRI data." In Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, vol. 2016, pp. 540–543. IEEE, 2016.
- [3] Hosseini-Asl, Ehsan, et al. "Alzheimer's disease diagnostics by a 3D deeply supervised adaptable convolutional network." Frontiers in Aging Neuroscience 10 (2018): 77.
- [4] Pereira, Sérgio, et al. "Brain tumor segmentation using convolutional neural networks in MRI images." IEEE Transactions on Medical Imaging 35.5 (2016): 1240–1251.
- [5] Islam, Jyoti, et al. "Alzheimer's disease diagnosis from brain MRI images using deep learning techniques." SN Computer Science 1.3 (2020): 167.
- [6] Sun, Jiaqi, et al. "Automatic brain tumor detection and segmentation using U-Net based fully convolutional networks." In 2017 IEEE 14th International Symposium on Biomedical Imaging (ISBI 2017). IEEE, 2017.
- [7] Esteva, Andre, et al. "A guide to deep learning in healthcare." Nature Medicine 25.1 (2019): 24–29.
- [8] Liu, Siqu, et al. "Application of deep learning in detecting brain tumor based on MRI images: a comprehensive review." Journal of Healthcare Engineering 2020 (2020): 8829251.
- [9] Kamnitsas, Konstantinos, et al. "Efficient multi-scale 3D CNN with fully connected CRF for accurate brain lesion segmentation." Medical Image Analysis 36 (2017): 61–78.
- [10] Shin, Hoo-Chang, et al. "Deep convolutional neural networks for computer-aided detection: CNN architectures, dataset characteristics and transfer learning." IEEE Transactions on Medical Imaging 35.5 (2016): 1285–1298.